Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma

Author:
  • E Bjorck
  • Sara Ek
  • O Landgren
  • Mats Jerkeman
  • Mats Ehinger
  • M Bjorkholm
  • Carl Borrebaeck
  • A Porwit-MacDonald
  • M Nordenskjold
Publishing year: 2005
Language: English
Pages: 2908-2915
Publication/Series: Blood
Volume: 105
Issue: 7
Document type: Journal article
Publisher: American Society of Hematology

Abstract english

Substantial research has been dedicated to the study of the relationship between genetic mechanisms regulating cell functions in tumors and how those tumors respond to various treatment regimens. Because these mechanisms are still not well understood, we have chosen to study the genetic makeup of 57 tumor samples from patients with follicular lymphoma (FL). Our goal was to develop a prognostic tool, which can be used as an aid in determining FL patients with tumors genetically predisposed to a successful treatment with the CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) regimen. To select relevant genes, high-density oligonucleotide arrays were used. There were 14 genes highly expressed in FL patients that responded well to CHOP chemotherapy, and 11 of these were involved in G(2)/M transition of the cell cycle, in mitosis, or in DNA modulation. A high expression of CCNB1 (cyclin B1), CDC2, CDKN3A, CKS1B, ANP32E, and KIAA0101, but not of the proliferation-related antigen Ki-67, was associated with better survival rate in a univariate analysis. CCNB1 expression had an independent prognostic value when included in a multivariate analysis together with the 5 parameters of the follicular lymphoma international prognostic index.

Keywords

  • Hematology

Other

Published
  • ISSN: 1528-0020
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se

Professor

Department of Immunotechnology

313k1

90

Director

Create Health

+46 46 222 96 13

313k1

90